Board of Directors
Arthur Kuan - Chief Executive Officer
Arthur currently serves as Chief Executive Officer and Director on the Board at Cold Genesys, a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies, including an oncolytic virus for the treatment of bladder cancer and a variety of other solid tumor types. Arthur is a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, and plays an active role in managing the fund’s portfolio companies. Previously, Arthur was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. He began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Arthur received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.
Luke Li, M.D. - Managing Director, Ally Bridge Group
Luke has 30 years of experience in biopharma and healthcare business. Currently, he is a Managing Director at Ally Bridge Group (“ABG”), a global healthcare investment platform, where he oversees biopharma investment opportunities for the healthcare fund and plays an important role in guiding science and business development for ABG’s portfolio companies. Before joining ABG, Luke was an Executive Director and the Head of Global Biotherapeutics, External R&D Innovation at Pfizer from 2010 to 2015, where he led search and evaluation as well as business development for in-licensing of innovative assets and cutting-edge technologies. He focused on Oncology, Biotechnologies, Pharmaceutical Sciences as well as Biosimilars to strengthen Pfizer’s pipeline. Luke served as Amgen’s Executive Director from 1993 to 2009, leading discovery research to IND, in which he advanced more than 3 dozen biologics into development, including several marketed products. From 1986 to 1992, Luke completed his fellowship training in Hematology/Oncology, and then became an Assistant Professor in Medicine at Washington University Medical School. Luke earned his M.D. from Fujian Medical University.
Ronald Cheng - Managing Director, Wellchamp Capital
Ronald has more than 20 years of experience in the Finance and Investment realm with an emphasis in media and biotechnology. He is the Founder and Managing Director at Wellchamp Capital Limited, a Hong Kong SFC registered asset management and investment advisory firm. In 2002, Ronald was Investor and Director of Plasmagene Bioscience, a biotechnology company founded by Dr. Alex Yeung, which eventually became listed as a part of the Hong Kong Stock Exchange (SEHK). Ronald was also Investor and Director of New Media Corp, a telecommunications media company invested in news and publication since 1975. Ronald holds a B.S. from The Chinese University of Hong Kong in Business Administration.
Simone Song - Senior Partner, ORI Capital
Simone is Founder and Senior Partner of ORI Capital. She was the former Head of Goldman Sachs Healthcare Investment Banking for Greater China. Simone has more than 25 years of experience in healthcare sector. Prior to joining Goldman Sachs, she was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers, and an executive board advisor to AXA Asia Pacific Holdings. Simone holds a B.A. in Economics from Fudan University in China and an M.A. in Economics from Claremont Graduate School in the United States.
James Yan - Partner, ORI Capital
James is Partner of ORI Capital. He was Executive Director at Goldman Sachs Asia investment banking division, involved in capital markets and M&A transactions. Prior to joining Goldman Sachs, he was an Associate of Macquarie Capital (Hong Kong), a member of the Macquarie Group, involved in direct investment and capital market transactions. James holds a B.Sc. in Accounting and Finance at London School of Economics and Political Science and a M.Phil. in Finance at the University of Cambridge.